诚达药业(301201) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥100,889,692.80, a decrease of 1.28% compared to ¥102,199,584.64 in the same period last year[5] - Net profit attributable to shareholders was ¥18,644,506.00, down 5.09% from ¥19,644,988.66 year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥10,245,947.59, representing a decline of 26.77% compared to ¥13,990,967.27 in the previous year[5] - Total operating costs for Q1 2024 were ¥88,945,893.49, an increase from ¥88,542,464.12 in the previous year[23] - The net profit for Q1 2024 was ¥18,726,286.19, down from ¥19,620,310.26 in Q1 2023, reflecting a decrease of approximately 4.56%[24] - Total comprehensive income for Q1 2024 was CNY 18,726,286.19, a decrease from CNY 19,620,310.26 in Q1 2023, representing a decline of approximately 4.56%[25] - Basic and diluted earnings per share for Q1 2024 were both CNY 0.1215, down from CNY 0.127 in Q1 2023, indicating a decrease of about 9.45%[25] Cash Flow - The net cash flow from operating activities decreased by 44.14% to ¥38,083,815.26 from ¥68,175,884.92 in the same period last year[5] - Cash inflow from operating activities totaled CNY 142,615,023.64, up from CNY 134,014,037.24 in the previous year, marking an increase of approximately 6.00%[27] - Cash outflow from operating activities increased to CNY 104,531,208.38, compared to CNY 65,838,152.32 in Q1 2023, reflecting a rise of about 58.73%[28] - Net cash flow from investing activities was negative CNY 147,278,645.13, a significant decrease from a positive CNY 739,885,063.10 in Q1 2023[28] - Cash and cash equivalents at the end of Q1 2024 stood at CNY 1,202,901,471.61, down from CNY 1,412,481,994.43 at the end of Q1 2023, a decrease of approximately 14.80%[28] - The company reported cash inflow from investment activities of CNY 9,388,395.89, down from CNY 784,871,003.70 in the previous year[28] - Total cash outflow from investment activities was CNY 156,667,041.02, compared to CNY 44,985,940.60 in Q1 2023, indicating a substantial increase[28] Assets and Liabilities - The total assets at the end of Q1 2024 were ¥2,403,749,254.49, a decrease of 2.10% from ¥2,455,325,018.15 at the end of the previous year[5] - The company's cash and cash equivalents decreased to RMB 1,202,901,471.61 from RMB 1,363,938,914.78 at the beginning of the period, a decline of approximately 11.76%[20] - The total liabilities decreased to RMB 157,846,542.20 from RMB 176,403,059.37, indicating a reduction of about 10.5%[22] - The company's retained earnings increased to RMB 391,831,207.29 from RMB 373,186,701.29, reflecting a growth of approximately 5.0%[22] Research and Development - R&D expenses increased by 105.63% to ¥9,782,578.34, primarily due to an increase in R&D projects and depreciation of completed R&D buildings[9] - Research and development expenses increased significantly to RMB 9,782,578.34 in Q1 2024, compared to RMB 4,757,398.07 in the same period last year, indicating a growth of 105.4%[24] Shareholder Information - The total number of common shareholders at the end of the reporting period is 15,429[12] - The largest shareholder, Ge Jianli, holds 27.17% of the shares, totaling 42,031,360 shares[12] - The second-largest shareholder, Huang Honglin, holds 12.62% of the shares, totaling 19,528,000 shares[12] - The company has a total of 67,520,000 restricted shares, with no shares released during the reporting period[16] Corporate Actions - The company repurchased shares, resulting in cash outflows of ¥51,941,867.10 during the financing activities[11] - The company plans to repurchase shares with a budget between RMB 30 million and RMB 60 million, with a maximum price of RMB 38.00 per share, within a 12-month period[18] - As of March 31, 2024, the company has repurchased 2,946,800 shares, accounting for 1.90% of the total share capital, with a total transaction amount of RMB 51,920,920.55[18] Subsidiary Developments - The company’s subsidiary, Chengjiutai, signed a technology cooperation agreement with Chiron Pharma for two clinical projects, which have received FDA approval[17] - The heart attack project has completed Phase 1 clinical trials and is now in Phase 2, while the brain stroke project is in Phase 1/2a clinical trials[17] - Chengjiutai purchased a factory in Shanghai with an area of 5,910.6 square meters for stem cell project development[17] Audit Status - The company has not undergone an audit for the Q1 2024 report[30]